NYSE: JNJ

Johnson & Johnson Releases 2018 Health for Humanity Report

Article

June 5, 2019 - Johnson & Johnson (NYSE: JNJ), the world’s largest and most broadly-based healthcare company, today released its Health for Humanity Report detailing the Company’s annual progress in its environmental, social and governance (ESG) focus areas: advancing better health for all, investing in our people, maintaining responsible business practices, and safeguarding the environment.

Tech That Protects: 3 Cutting-Edge Innovations That Can Help Make Your Next Surgery Safer

By Kristen Mascia
Summary: 

From a pencil that hoovers up potentially toxic surgical smoke to a 3-D tool that helps reduce exposure to radiation, these Johnson & Johnson Medical Devices Companies advances were designed with one thing in mind: protecting patients and the doctors delivering their care.

Article

From a pencil that hoovers up potentially toxic surgical smoke to a 3-D tool that helps reduce exposure to radiation, these Johnson & Johnson Medical Devices Companies advances were designed with one thing in mind: protecting patients and the doctors delivering their care.

Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention

Press Release

Johnson & Johnson to collaborate with Apple to assess impact of wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes

Up to 30 percent of AFib cases go undiagnosed until life-threatening complications occur, signaling a critical need for more efficient and scalable screening methods

J&J Exec: Tuberculosis is a Global Emergency. It's Time to Start Treating it That Way

By Paul Stoffels
Summary: 
  • Ebola, and HIV before it, shows what can be accomplished once a disease is catapulted to the top of the global agenda.
     
  • Dr. Paul Stoffels, Johnson & Johnson's chief scientific officer, says tuberculosis is a far deadlier disease, but has not received this sort of attention and focus from the global community.
     
  • An outdated and inadequate toolbox is largely to blame for the unacceptably high toll of TB.
Article
  • Ebola, and HIV before it, shows what can be accomplished once a disease is catapulted to the top of the global agenda.
     
  • Dr. Paul Stoffels, Johnson & Johnson's chief scientific officer, says tuberculosis is a far deadlier disease, but has not received this sort of attention and focus from the global community.
     
  • An outdated and inadequate toolbox is largely to blame for the unacceptably high toll of TB.

Meet a Johnson & Johnson Researcher Poised to Crack the HIV Vaccine Code

In the lead-up to the recent International AIDS Society Conference on HIV Science in the Netherlands, we sat down with Hanneke Schuitemaker, who's hard at work on the holy grail of HIV research: a preventive treatment.
Article

By Sheila Weller

In 1992, as a young HIV/AIDS researcher in her native Netherlands, Hanneke Schuitemaker, Ph.D., now Vice President, Global Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V., was devoted to learning as much as she could about the disease—and saw her role as that of a researcher, rather than someone who closely interacted with people who were living with HIV.

But that quickly changed.

Subscribe to NYSE: JNJ